AstraZeneca, Daiichi Sankyo win first U.S. popularity of key most cancers drug – The Gentleman Report | World | Business | Science | Technology | Health
Today: Jul 29, 2025

AstraZeneca, Daiichi Sankyo win first U.S. popularity of key most cancers drug

AstraZeneca, Daiichi Sankyo win first U.S. popularity of key most cancers drug
January 20, 2025



A next-generation type of chemotherapy from AstraZeneca and Daiichi Sankyo has received Meals and Drug Management authorization for a type of breast most cancers, the primary U.S. popularity of a drug for which the corporations have top expectancies. 

The FDA on Friday introduced it had authorized the drug, to be advertised as Datroway, for positive complicated breast most cancers sufferers. Datroway, often known as datopotamab deruxtecan, or Dato-DXd, was once authorized in Japan for a type of breast most cancers final month, its first regulatory inexperienced gentle.

The U.S. checklist worth for Datroway is kind of $4,900 in line with 100 milligram vial, and the really useful dose of the drug is 6 milligrams in line with kilogram of affected person weight each and every 3 weeks. 

STAT+ Unique Tale
Have already got an account? Log in

AstraZeneca, Daiichi Sankyo win first U.S. popularity of key most cancers drug

This text is unique to STAT+ subscribers
Liberate this text — plus day by day protection and research of the pharma trade — via subscribing to STAT+.
Have already got an account? Log in

Particular person plans

Team plans

View All Plans

To learn the remainder of this tale subscribe to STAT+.
Subscribe

OpenAI
Author: OpenAI

Don't Miss

UnitedHealth says 2025 profits will likely be worse than anticipated as prime scientific prices canine insurers

UnitedHealth says 2025 profits will likely be worse than anticipated as prime scientific prices canine insurers

UnitedHealth Staff on Tuesday issued a 2025 outlook that fell wanting Wall
Merck plans  billion price cuts by way of finish of 2027, narrows full-year outlook

Merck plans $3 billion price cuts by way of finish of 2027, narrows full-year outlook

Merck & Co. signage at the ground of the New York Inventory